Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

C-peptide in diabetes diagnosis and therapy.

Ludvigsson J.

Front Biosci (Elite Ed). 2013 Jan 1;5:214-23. Review.

PMID:
23276983
2.

Residual C-peptide in type 1 diabetes: what do we really know?

VanBuecken DE, Greenbaum CJ.

Pediatr Diabetes. 2014 Mar;15(2):84-90. doi: 10.1111/pedi.12135. Review.

PMID:
24645775
3.
4.

Immune intervention at diagnosis--should we treat children to preserve beta-cell function?

Ludvigsson J.

Pediatr Diabetes. 2007 Oct;8 Suppl 6:34-9.

PMID:
17727383
5.

C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001.

Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM, Polonsky KS, Pozzilli P, Skyler JS, Steffes MW.

Diabetes. 2004 Jan;53(1):250-64. Erratum in: Diabetes. 2004 Jul;53(7):1934.

7.

Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials.

Schloot NC, Meierhoff G, Lengyel C, Vándorfi G, Takács J, Pánczél P, Barkai L, Madácsy L, Oroszlán T, Kovács P, Sütö G, Battelino T, Hosszufalusi N, Jermendy G.

Diabetes Metab Res Rev. 2007 May;23(4):276-85.

PMID:
17103487
8.

Diabetes technology and treatments in the paediatric age group.

Shalitin S, Peter Chase H.

Int J Clin Pract Suppl. 2011 Feb;(170):76-82. doi: 10.1111/j.1742-1241.2010.02582.x. Review.

PMID:
21323816
9.

The clinical potential of low-level C-peptide secretion.

Ludvigsson J.

Expert Rev Mol Diagn. 2016 Sep;16(9):933-940. doi: 10.1080/14737159.2016.1210513. Epub 2016 Jul 18. Review.

PMID:
27388792
10.

Beta-cell function and mass in type 2 diabetes.

Larsen MO.

Dan Med Bull. 2009 Aug;56(3):153-64.

PMID:
19728971
11.

Clinical manifestations and beta cell function in Swedish diabetic children have remained unchanged during the last 25 years.

Nordwall M, Ludvigsson J.

Diabetes Metab Res Rev. 2008 Sep;24(6):472-9. doi: 10.1002/dmrr.871.

PMID:
18613248
12.

Proinsulin C-peptide: friend or foe in the development of diabetes-associated complications?

Nordquist L, Johansson M.

Vasc Health Risk Manag. 2008;4(6):1283-8. Review.

13.

Metabolic factors affecting residual beta cell function assessed by C-peptide secretion in patients with newly diagnosed type 1 diabetes.

Picardi A, Visalli N, Lauria A, Suraci C, Buzzetti R, Merola MK, Manfrini S, Guglielmi C, Gentilucci UV, Pitocco D, Crinò A, Bizzarri C, Cappa M, Pozzilli P.

Horm Metab Res. 2006 Oct;38(10):668-72.

PMID:
17075776
14.

[C-peptide residual secretion makes difference on type 1 diabetes management?].

Rodacki M, Milech A, Oliveira JE.

Arq Bras Endocrinol Metabol. 2008 Mar;52(2):322-33. Review. Portuguese.

15.
16.

Insulin and C-peptide levels, pancreatic beta cell function, and insulin resistance across glucose tolerance status in Thais.

Chailurkit LO, Jongjaroenprasert W, Chanprasertyothin S, Ongphiphadhanakul B.

J Clin Lab Anal. 2007;21(2):85-90.

PMID:
17385686
17.

Persistent C-peptide: what does it mean?

Pietropaolo M.

Curr Opin Endocrinol Diabetes Obes. 2013 Aug;20(4):279-84. doi: 10.1097/MED.0b013e3283628610. Review.

PMID:
23743645
18.

[Role of C-peptide in the pathogenesis of diabetic nephropathy].

Martina V, Maestroni A, Maestroni S, Zerbini G.

G Ital Nefrol. 2010 May-Jun;27(3):240-8. Review. Italian.

PMID:
20540017
19.

Protective effects of 1-alpha-hydroxyvitamin D3 on residual beta-cell function in patients with adult-onset latent autoimmune diabetes (LADA).

Li X, Liao L, Yan X, Huang G, Lin J, Lei M, Wang X, Zhou Z.

Diabetes Metab Res Rev. 2009 Jul;25(5):411-6. doi: 10.1002/dmrr.977.

PMID:
19488999
20.

Use of technology to potentially preserve C-Peptide in type 1 diabetes mellitus.

Danne T, Kordonouri O.

Pediatr Endocrinol Rev. 2010 Aug;7 Suppl 3:396-400. Review.

PMID:
20877252

Supplemental Content

Support Center